Search - tctmd.com

Displaying 21 - 40 of 221

Sort: Relevancy | Date

Presentation TCT 2024

Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery: The SIRONA Randomized Controlled Trial

Presenter: Ulf Teichgräber

October 29, 2024

Presentation TCT 2024

TCT 497: Sex-Specific Clinical Outcomes After Treatment of In-Stent Restenosis With the AGENT Paclitaxel-Coated Balloon: A Subgroup Analysis of the AGENT IDE Randomized Trial

Presenter: Jennifer Tremmel

October 29, 2024

Presentation TCT 2024

TCT 700: Drug-Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons

Presenter: Linnea Tscheuschner

October 29, 2024

Presentation TCT 2024

TCT 455: Quantitative Coronary Dissection Volume After Sirolimus or Paclitaxel Coated Balloon and Lumen Changes at 6 Months: Serial OCT Sub-study of TRANSFORM-I Trial

Presenter: Akihiro Tobe

October 29, 2024

Presentation TCT 2024

TCT 451: Plaque Changes and Vessel Remodeling After Balloon Angioplasty for De Novo Coronary Lesions Using Paclitaxel-Coated Balloons: A Serial IB-IVUS Study

Presenter: Shelby Kerr

October 29, 2024

Presentation TCT 2024

TCT 41: Paclitaxel-Coated Versus Sirolimus-Coated Balloon Angioplasty for Coronary Artery Disease: A Systematic Review and Meta-Analysis

Presenter: Doosup Shin

October 28, 2024

Presentation TCT 2024

TCT 40: Sirolimus- vs. Paclitaxel-Coated Balloons for Treatment of Coronary Artery Disease

Presenter: Pier Pasquale Leone

October 28, 2024

Presentation TCT 2024

TCT 491: AGENT Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis in Small Vessel Coronary Lesions: A Subgroup Analysis of the AGENT IDE Randomized Trial

Presenter: Suhail Dohad

October 28, 2024

Presentation TCT 2024

TCT 436: Paclitaxel-Coated Balloon With Urea or Iopromide as the Excepient for Treatment of Coronary Artery Disease: A Propensity-Score Adjusted Comparison

Presenter: Mauro Gitto

October 28, 2024

Presentation TCT 2024

TCT 492: One-Year Clinical Outcomes After PCI With AGENT Paclitaxel-Coated Balloon Among Underrepresented Racial and Ethnic Subgroups With In-Stent Restenosis: Analysis of the AGENT IDE Trial

Presenter: NULL

October 28, 2024

Presentation TCT 2024

TCT 446: Long-term Outcomes and Impact of Diabetes Mellitus in Patients Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

Presenter: Gakuto Bando

October 28, 2024

News Conference News ESC 2024

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

Todd Neale

September 09, 2024

Podcast TCTMD Talking Points

The AGENT IDE Trial

June 05, 2024

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

News Daily News

As US Rollout Begins for Coronary DCBs, Interventionalists Mull Practice Changes

Todd Neale

May 03, 2024

News Daily News

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

L.A. McKeown

March 25, 2024

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

L.A. McKeown

March 09, 2024

News Daily News

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

L.A. McKeown

March 01, 2024

Presentation Miami Valves 2024

Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Balloon With Conventional Balloon Angioplasty for In-Stent Restenosis

Presenter: Thomas E. Noel

February 01, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

Advertisement

Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery: The SIRONA Randomized Controlled Trial

TCT 497: Sex-Specific Clinical Outcomes After Treatment of In-Stent Restenosis With the AGENT Paclitaxel-Coated Balloon: A Subgroup Analysis of the AGENT IDE Randomized Trial

TCT 700: Drug-Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons

TCT 455: Quantitative Coronary Dissection Volume After Sirolimus or Paclitaxel Coated Balloon and Lumen Changes at 6 Months: Serial OCT Sub-study of TRANSFORM-I Trial

TCT 451: Plaque Changes and Vessel Remodeling After Balloon Angioplasty for De Novo Coronary Lesions Using Paclitaxel-Coated Balloons: A Serial IB-IVUS Study

TCT 41: Paclitaxel-Coated Versus Sirolimus-Coated Balloon Angioplasty for Coronary Artery Disease: A Systematic Review and Meta-Analysis

TCT 40: Sirolimus- vs. Paclitaxel-Coated Balloons for Treatment of Coronary Artery Disease

TCT 491: AGENT Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis in Small Vessel Coronary Lesions: A Subgroup Analysis of the AGENT IDE Randomized Trial

TCT 436: Paclitaxel-Coated Balloon With Urea or Iopromide as the Excepient for Treatment of Coronary Artery Disease: A Propensity-Score Adjusted Comparison

TCT 492: One-Year Clinical Outcomes After PCI With AGENT Paclitaxel-Coated Balloon Among Underrepresented Racial and Ethnic Subgroups With In-Stent Restenosis: Analysis of the AGENT IDE Trial

TCT 446: Long-term Outcomes and Impact of Diabetes Mellitus in Patients Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

The AGENT IDE Trial

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

As US Rollout Begins for Coronary DCBs, Interventionalists Mull Practice Changes

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Balloon With Conventional Balloon Angioplasty for In-Stent Restenosis

Top Endovascular News of 2023

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content